Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Top-line data from an open-label, U.S. and South Korean Phase II trial in 115 patients with metastatic RCC who progressed after 2-3 prior lines of therapy showed that 15 mg/m 2 IV CRLX101 on days 1 an...